Teijin subsidiary J-TEC to establish German subsidiary
The new entity, Japan Tissue Engineering Europe GmbH, will manufacture and sell LabCyte models, accelerating European expansion.
See the latest news and media coverage for Teijin. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global technology group in materials and healthcare
teijin.comLast updated
In short: Teijin reported strong fiscal results and shifted its pharmaceutical strategy to focus on rare diseases by divesting several products.
The new entity, Japan Tissue Engineering Europe GmbH, will manufacture and sell LabCyte models, accelerating European expansion.
The new entity, TA Frontier, will be established on October 1, 2026, with Teijin holding 80% and Asahi Kasei 20%.
Impairment loss of 25.4 billion yen on diabetes drug assets; gain of around 45.5 billion yen from selling DuPont Teijin Advanced Papers shares.
The natural gas-fired system reduces CO2 emissions by 200,000 tons annually and eliminates coal use.
Teijin announced on the 17th that it will sell part of its pharmaceutical business to LTL Pharma (Shinjuku, Tokyo). The target is the rights to manufacture and sell seven products including a gout drug, and the sale price is undisclosed. The company has already factored this into its earnings forecast for the fiscal year ending March 2027. Teijin is proceeding with restructuring of pharmaceuticals other than rare diseases by selling them off. The pharmaceutical business is handled by Teijin Pharma (Chiyoda, Tokyo), a subsidiary of Teijin. Among the products to be sold is the gout drug 'Febu...' which previously drove performance with annual sales of about 39 billion yen in Japan.
Teijin Pharma Limited, the core company of the Teijin Group's healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced...
Shimai, Financial Officer/CFO, Teijin Limited: I will now explain the fiscal 2025 results and fiscal 2026 earnings outlook. First, regarding key points from the earnings...
I will now explain the fiscal 2025 results and fiscal 2026 earnings outlook. First, regarding key points from the earnings announcement, fiscal 2025 adjusted operating...
Track Teijin and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Teijin and other trending companies.